Literature DB >> 23291290

Feeder-independent derivation of induced-pluripotent stem cells from peripheral blood endothelial progenitor cells.

Wing Y Chang1, Jessie R Lavoie, Sarah Y Kwon, Zhaoyi Chen, Janet L Manias, John Behbahani, Vicki Ling, Rita A Kandel, Duncan J Stewart, William L Stanford.   

Abstract

Induced-pluripotent stem cells (iPSCs) are a potential alternative cell source in regenerative medicine, which includes the use of differentiated iPSCs for cell therapies to treat coronary artery and/or peripheral arterial diseases. Late-outgrowth endothelial progenitor cells (late-EPCs) are a unique primary cell present in peripheral blood that exhibit high proliferative capacity, are being used in a wide variety of clinical trials, and have the ability to differentiate into mature endothelial cells. The objective of this study was to reprogram peripheral blood-derived late-EPCs to a pluripotent state under feeder-free and defined culture conditions. Late-EPCs that were retrovirally transduced with OCT4, SOX2, KLF4, c-MYC, and iPSC colonies were derived in feeder-free and defined media conditions. EPC-iPSCs expressed pluripotent markers, were capable of differentiating to cells from all three germ-layers, and retained a normal karyotype. Transcriptome analyses demonstrated that EPC-iPSCs exhibit a global gene expression profile similar to human embryonic stem cells (hESCs). We have generated iPSCs from late-EPCs under feeder-free conditions. Thus, peripheral blood-derived late-outgrowth EPCs represent an alternative cell source for generating iPSCs.
Copyright © 2012 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23291290     DOI: 10.1016/j.scr.2012.11.006

Source DB:  PubMed          Journal:  Stem Cell Res        ISSN: 1873-5061            Impact factor:   2.020


  7 in total

1.  Human Pluripotent Stem Cell-Derived TSC2-Haploinsufficient Smooth Muscle Cells Recapitulate Features of Lymphangioleiomyomatosis.

Authors:  Lisa M Julian; Sean P Delaney; Ying Wang; Alexander A Goldberg; Carole Doré; Julien Yockell-Lelièvre; Roger Y Tam; Krinio Giannikou; Fiona McMurray; Molly S Shoichet; Mary-Ellen Harper; Elizabeth P Henske; David J Kwiatkowski; Thomas N Darling; Joel Moss; Arnold S Kristof; William L Stanford
Journal:  Cancer Res       Date:  2017-08-22       Impact factor: 12.701

2.  Inhibition of apoptosis in human induced pluripotent stem cells during expansion in a defined culture using angiopoietin-1 derived peptide QHREDGS.

Authors:  Lan T H Dang; Nicole T Feric; Carol Laschinger; Wing Y Chang; Boyang Zhang; Geoffrey A Wood; William L Stanford; Milica Radisic
Journal:  Biomaterials       Date:  2014-06-13       Impact factor: 12.479

3.  Reprogramming progeria fibroblasts re-establishes a normal epigenetic landscape.

Authors:  Zhaoyi Chen; Wing Y Chang; Alton Etheridge; Hilmar Strickfaden; Zhigang Jin; Gareth Palidwor; Ji-Hoon Cho; Kai Wang; Sarah Y Kwon; Carole Doré; Angela Raymond; Akitsu Hotta; James Ellis; Rita A Kandel; F Jeffrey Dilworth; Theodore J Perkins; Michael J Hendzel; David J Galas; William L Stanford
Journal:  Aging Cell       Date:  2017-06-08       Impact factor: 9.304

4.  Transcriptomically Guided Mesendoderm Induction of Human Pluripotent Stem Cells Using a Systematically Defined Culture Scheme.

Authors:  Richard L Carpenedo; Sarah Y Kwon; R Matthew Tanner; Julien Yockell-Lelièvre; Chandarong Choey; Carole Doré; Mirabelle Ho; Duncan J Stewart; Theodore J Perkins; William L Stanford
Journal:  Stem Cell Reports       Date:  2019-12-10       Impact factor: 7.765

5.  Derivation and expansion of PAX7-positive muscle progenitors from human and mouse embryonic stem cells.

Authors:  Michael Shelton; Jeff Metz; Jun Liu; Richard L Carpenedo; Simon-Pierre Demers; William L Stanford; Ilona S Skerjanc
Journal:  Stem Cell Reports       Date:  2014-08-07       Impact factor: 7.765

6.  Autologous and Heterologous Cell Therapy for Hemophilia B toward Functional Restoration of Factor IX.

Authors:  Suvasini Ramaswamy; Nina Tonnu; Tushar Menon; Benjamin M Lewis; Kevin T Green; Derek Wampler; Paul E Monahan; Inder M Verma
Journal:  Cell Rep       Date:  2018-05-01       Impact factor: 9.423

Review 7.  Human Induced Pluripotent Stem Cell as a Disease Modeling and Drug Development Platform-A Cardiac Perspective.

Authors:  Mohamed M Bekhite; P Christian Schulze
Journal:  Cells       Date:  2021-12-09       Impact factor: 6.600

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.